A New Axis in Autoimmune Care: The Baricitinib Market Landscape...

agregó una foto Other

2025-09-26 13:12:44 -

A New Axis in Autoimmune Care: The Baricitinib Market Landscape Industry Trends and Forecast to 2029

The baricitinib market is expected to witness market growth at a rate of 11.90% in the forecast period of 2022 to 2029. Baricitinib, a small-molecule Janus kinase (JAK) inhibitor sold most widely under the brand name Olumiant (Eli Lilly/Incyte), has evolved from a rheumatoid-arthritis therapy into a multi-indication platform with growing commercial footprint. Beyond its original approval for...

0 Commentarios 0 Acciones 170 Views 0 Vista previa